Silence Therapeutics Appoints Michael H. Davidson, MD, to Board of Directors
06 janv. 2021 07h00 HE
|
Silence Therapeutics plc
Silence Therapeutics Appoints Michael H. Davidson, MD, to Board of Directors Leading expert in lipidology to support Silence as it advances new approach to treating cardiovascular disease with lead...
Silence Therapeutics to Participate in January Virtual U.S. Investor Conferences
05 janv. 2021 07h00 HE
|
Silence Therapeutics plc
Silence Therapeutics to Participate in January Virtual U.S. Investor Conferences 5 January 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in...
Silence Therapeutics Presents Positive Pre-Clinical Data for SLN360 for the Treatment of Elevated Lipoprotein(a) at American Heart Association 2020
16 nov. 2020 07h00 HE
|
Silence Therapeutics plc
Silence Therapeutics Presents Positive Pre-Clinical Data for SLN360 for the Treatment of Elevated Lipoprotein(a) at American Heart Association 2020 Pre-clinical safety data show no adverse or...
Silence Therapeutics Appoints Dr. Marie Wikström Lindholm to its Executive Leadership Team
02 nov. 2020 07h00 HE
|
Silence Therapeutics plc
Silence Therapeutics Appoints Dr. Marie Wikström Lindholm to its Executive Leadership Team – Dr. Lindholm’s appointment reflects the Company’s commitment to maximise the siRNA...
Silence Therapeutics Announces Change to Executive Leadership Team
08 oct. 2020 07h00 HE
|
Silence Therapeutics plc
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE...
Silence Therapeutics to Participate in the Chardan Virtual 4th Annual Genetic Medicines Conference
01 oct. 2020 07h00 HE
|
Silence Therapeutics plc
Silence Therapeutics to Participate in the Chardan Virtual 4th Annual Genetic Medicines Conference 1 October 2020 LONDON, Silence Therapeutics plc (AIM: SLN) and (Nasdaq: SLN) (“Silence” or “the...
Silence Therapeutics Appoints Mark Rothera as President and Chief Executive Officer
14 sept. 2020 07h00 HE
|
Silence Therapeutics
Silence Therapeutics Appoints Mark Rothera as President and Chief Executive Officer Experienced biotech executive to lead the next phase of growth 14 September 2020 LONDON, Silence Therapeutics...
Silence Therapeutics Reports Interim Results for the Six Months Ended 30 June 2020
14 sept. 2020 07h00 HE
|
Silence Therapeutics
Silence Therapeutics Reports Interim Results for the Six Months Ended 30 June 2020 14 September 2020 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN (“Silence” or “the Group”), a leader in...
Silence Therapeutics Provides Research and Development Update
08 sept. 2020 07h00 HE
|
Silence Therapeutics
Silence Therapeutics Provides Research and Development Update IND approval received for SLN360 to start dose escalation studies Dosing initiated for SLN124, the first dose of a Silence GalNAc-siRNA...
Silence Therapeutics Announces Instructions for Exchanging Listed Ordinary Shares into Nasdaq Listed ADSs
08 sept. 2020 07h00 HE
|
Silence Therapeutics
Silence Therapeutics Announces Instructions for Exchanging Listed Ordinary Shares into Nasdaq Listed ADSs 8 September 2020 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN (“Silence” or...